TY - JOUR
T1 - Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease
AU - Jacobson, Denise L.
AU - Wu, Albert W.
AU - Feinberg, Judith
N1 - Funding Information:
We thank Richard Berzon, Jo Mauskopf, and Dion Coakley for their help in developing this project. We thank the patients who generously donated their time and energy to this study. This research was supported in part by the Johns Hopkins University Adult Clinical Trials Unit Grant no. U01 A138858, the Adult AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases, Cooperative Agreement No. U01 AI38858, and Glaxo Wellcome, Inc.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - We tested whether health related quality of life (HRQOL) predicts mortality, development of active cytomegalovirus (CMV) disease, and study retention. We studied 957 patients with CD4 counts <100 cells/mm3 in AIDS Clinical Trials Group Protocol 204, a randomized, double-blind trial comparing three prophylactic regimens against CMV end-organ disease. The MOS-HIV, a brief HRQOL questionnaire, generated physical health summary (PHS) and mental health summary (MHS) scores. We used Cox proportional hazards to predict events by baseline HRQOL, adjusted for treatment, demographics, and CD4. Each point increase in baseline PHS decreased the risk of death by 4%, CMV by 2%, and dropout by 2%. Each point increase in baseline MHS decreased the risk of death by 4% and study dropout by 1%. In conclusion, self-rated physical and mental health demonstrated predictive validity for survival, CMV end-organ disease, and retention in advanced HIV patients. The results show the clinical importance of HRQOL and may facilitate interpretation by clinicians.
AB - We tested whether health related quality of life (HRQOL) predicts mortality, development of active cytomegalovirus (CMV) disease, and study retention. We studied 957 patients with CD4 counts <100 cells/mm3 in AIDS Clinical Trials Group Protocol 204, a randomized, double-blind trial comparing three prophylactic regimens against CMV end-organ disease. The MOS-HIV, a brief HRQOL questionnaire, generated physical health summary (PHS) and mental health summary (MHS) scores. We used Cox proportional hazards to predict events by baseline HRQOL, adjusted for treatment, demographics, and CD4. Each point increase in baseline PHS decreased the risk of death by 4%, CMV by 2%, and dropout by 2%. Each point increase in baseline MHS decreased the risk of death by 4% and study dropout by 1%. In conclusion, self-rated physical and mental health demonstrated predictive validity for survival, CMV end-organ disease, and retention in advanced HIV patients. The results show the clinical importance of HRQOL and may facilitate interpretation by clinicians.
KW - Clinical trial
KW - Cytomegalovirus
KW - Health-related quality of life
KW - Outcomes
KW - Study retention
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0141849360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141849360&partnerID=8YFLogxK
U2 - 10.1016/S0895-4356(03)00062-3
DO - 10.1016/S0895-4356(03)00062-3
M3 - Article
C2 - 14505773
AN - SCOPUS:0141849360
SN - 0895-4356
VL - 56
SP - 874
EP - 879
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
IS - 9
ER -